Live Breaking News & Updates on Newly Diagnosed All

Stay updated with breaking news from Newly diagnosed all. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS. ....

Hagopm-kantarjian , Bijald-shah , Acute-lymphoblastic-leukemia , Call-cancer , Oph-all , Ph-acute-lymphoblastic-leukemia , Philadelphia-chromosome-positive-acute-lymphoblastic-leukemia , Newly-diagnosed-all , Newly-diagnosed-acute-lymphoblastic-leukemia , Ponatinib-based-therapy , Ponatinib-safety

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment. ....

Bijal-shah , Hagop-kantarjian , Expert-insights , Newly-diagnosed , Frontline-therapy , Acute-lymphoblastic-leukemia , Call-cancer , Oph-all , Ph-acute-lymphoblastic-leukemia , Philadelphia-chromosome-positive-acute-lymphoblastic-leukemia , Newly-diagnosed-all

Advancing the Treatment Landscape in Philadelphia-Positive ALL

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival. ....

Philadelphia , Pennsylvania , United-states , Expert-insights , Newly-diagnosed , Treatment-landscape , Acute-lymphoblastic-leukemia , Call-cancer , Oph-all , Ph-acute-lymphoblastic-leukemia , Philadelphia-chromosome-positive-acute-lymphoblastic-leukemia